PBC Medications

by | Apr 6, 2026 | Blog | 0 comments

There’s an important article titled “Par for the course? Comparative effectiveness of PPAR agonists in PBC” from April 2026 in Hepatology by Robert M. Wilechansky, and it’s summarized below–


🧠 Summary

1) Context: why this matters

  • Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease.
  • Ursodeoxycholic acid (UDCA) is first-line, but ~30–40% of patients have incomplete response.
  • This has created strong interest in PPAR agonists as second-line therapies.

2) What the article is about

  • This is a commentary/editorial, not a primary trial.
  • It discusses a comparative effectiveness (network meta-analysis) of different PPAR agonists (e.g., bezafibrate, fenofibrate, elafibranor, seladelpar).
  • Focus: How do these drugs compare—not just vs placebo, but against each other?

3) Key takeaways

âś… PPAR agonists clearly work (class effect)

  • Across studies, PPAR agonists:
    • Improve alkaline phosphatase (ALP) and other cholestatic markers
    • Increase biochemical response rates
  • This supports their role as effective second-line therapy in PBC.

⚖️ Differences between agents are modest and uncertain

  • Comparative analyses suggest some variation in efficacy between drugs, but:
    • Differences are not dramatic
    • Evidence is indirect (network meta-analysis) rather than head-to-head trials
  • Bottom line: no clear “best” PPAR agonist yet

🧪 Surrogate endpoints dominate

  • Most data rely on biochemical markers (ALP, GGT, bilirubin)
  • These are important—but:
    • Hard clinical outcomes (transplant-free survival, mortality) remain limited
  • The article emphasizes caution in overinterpreting surrogate-driven rankings

đź’Š Real-world practicality matters

  • Older drugs (e.g., bezafibrate) have:
    • Longer real-world experience
    • Lower cost
  • Newer agents (e.g., seladelpar, elafibranor) have:
    • Strong trial data
    • Regulatory momentum
  • The commentary highlights a tension between innovation vs practicality

⚠️ Evidence gaps

  • Lack of:
    • Head-to-head RCTs
    • Long-term outcomes data
  • Heterogeneity across trials (populations, endpoints, designs) limits firm conclusions

4) The Core Insight

  • The title reflects the main conclusion:
    • Comparative effectiveness studies often show small differences and uncertainty
    • That’s expected (“par for the course”) in evolving therapeutic classes
  • Clinicians should:
    • Avoid overinterpreting rankings
    • Focus on patient-specific factors + availability + safety

🧾 Bottom line

  • PPAR agonists are a major advance in PBC treatment.
  • But:
    • They likely represent a class effect
    • No single agent clearly dominates yet
  • Clinical decision-making should remain pragmatic, not purely data-driven by indirect comparisons.